PMID- 25833149
OWN - NLM
STAT- MEDLINE
DCOM- 20151106
LR  - 20190221
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 89
IP  - 3
DP  - 2015
TI  - Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional 
      Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from 
      Brazil.
PG  - 175-86
LID - 10.1159/000376552 [doi]
AB  - AIM: To show additional prognostic information about the mutational profile and 
      new International Association for the Study of Lung Cancer/American Thoracic 
      Society/European Respiratory Society (IASLC/ATS/ERS) classification of 
      adenocarcinoma (ADC) in patients without epidermal growth factor receptor 
      (EGFR)-tyrosine kinase inhibitor treatments. METHODS: In human lung ADC patients 
      (n = 125), including 24 lepidic, 67 acinar, 23 papillary, and 11 solid 
      predominant subtypes, EGFR and KRAS were sequenced, and anaplastic lymphoma 
      kinase (ALK) rearrangements were screened using fluorescence in situ 
      hybridization (FISH). RESULTS: EGFR was mutated in 21.6% of patients with 19.57% 
      showing a mean expression. The most frequent EGFR mutation was a deletion in exon 
      19, followed by an L858R amino acid substitution in exon 21. KRAS was mutated in 
      26.4% of patients with 50% displaying mean expression. ALK rearrangement was 
      detected in 6 patients (4.8%). Predominant acinar ADC was strongly associated 
      with EGFR and KRAS mutation. Clinical stage, lymph node metastases, and EGFR 
      mutation in exon 18 showed a significant difference in disease-free and overall 
      survival, but only a trend significance for EGFR and KRAS mutations. Multivariate 
      analysis revealed that men aged >71 years, with a history of smoking (<72 
      packs/year), clinical stage I/II, and acinar histologic subtype presented better 
      survival than women aged </= 71 years, with a history of smoking (>72 packs/year), 
      and having a predominant solid ADC and EGFR mutation in exon 18. CONCLUSIONS: 
      These results indicate that the mutational profile and new IASLC/ATS/ERS 
      classification provide additional prognostic information about lung ADC.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - de Melo, Andreia Cristina
AU  - de Melo AC
AD  - Department of Pathology, Faculdade de Medicina da Universidade de Sao Paulo, Sao 
      Paulo, Brazil.
FAU - Karen de Sa, Vanessa
AU  - Karen de Sa V
FAU - Sternberg, Cinthya
AU  - Sternberg C
FAU - Olivieri, Eloisa Ribeiro
AU  - Olivieri ER
FAU - Werneck da Cunha, Isabela
AU  - Werneck da Cunha I
FAU - Fabro, Alexandre Todorovic
AU  - Fabro AT
FAU - Carraro, Dirce Maria
AU  - Carraro DM
FAU - de Barros e Silva, Milton Jose
AU  - de Barros e Silva MJ
FAU - Pimenta Inada, Haynna Kimie
AU  - Pimenta Inada HK
FAU - de Mello, Evandro Sobrosa
AU  - de Mello ES
FAU - Soares, Fernando Augusto
AU  - Soares FA
FAU - Takagaki, Tereza
AU  - Takagaki T
FAU - Ferreira, Carlos Gil
AU  - Ferreira CG
FAU - Capelozzi, Vera Luiza
AU  - Capelozzi VL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150401
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (KRAS protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adenocarcinoma/*classification/etiology/*genetics/mortality/pathology
MH  - Adenocarcinoma of Lung
MH  - Adenocarcinoma, Papillary/genetics
MH  - Aged
MH  - Aged, 80 and over
MH  - Amino Acid Substitution
MH  - Anaplastic Lymphoma Kinase
MH  - Brazil
MH  - Carcinoma, Acinar Cell/genetics
MH  - Disease-Free Survival
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Gene Deletion
MH  - Gene Expression Regulation, Neoplastic
MH  - *Gene Rearrangement
MH  - Humans
MH  - Lung Neoplasms/*classification/etiology/*genetics/mortality/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Mutation Rate
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins p21(ras)
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - Survival Analysis
MH  - *Transcriptome
MH  - ras Proteins/*genetics
EDAT- 2015/04/03 06:00
MHDA- 2015/11/07 06:00
CRDT- 2015/04/03 06:00
PHST- 2014/12/04 00:00 [received]
PHST- 2015/01/27 00:00 [accepted]
PHST- 2015/04/03 06:00 [entrez]
PHST- 2015/04/03 06:00 [pubmed]
PHST- 2015/11/07 06:00 [medline]
AID - 000376552 [pii]
AID - 10.1159/000376552 [doi]
PST - ppublish
SO  - Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.